DEBRA Research gGmbH

DEBRA Research gGmbH develops treatments and cures for Epidermolysis Bullosa (EB). It focuses on translational research and clinical development, identifying, funding, and advancing promising therapies. The organization builds critical research infrastructure, like patient registries and trial networks, and leads in-house therapeutic development for this rare genetic disorder. This comprehensive approach aims to accelerate scientific progress toward viable treatments.

Established in 2019, DEBRA Research gGmbH is the global research arm of DEBRA Austria. Its formation addressed urgent medical needs of individuals with EB, centralizing and intensifying research efforts. It unites global experts from scientific, industrial, and regulatory fields to drive therapeutic solutions for patient benefit. The organization’s founding insight centered on the critical need for a coordinated, international research initiative.

DEBRA Research gGmbH serves the global community affected by Epidermolysis Bullosa, striving to improve patient lives. Its mission is to identify and propel therapeutic approaches that alleviate symptoms and ultimately cure EB. The organization envisions a future where EB is curable, enabling affected individuals to achieve their best possible quality of life through sustained research and development.